Article Sidebar

PDF (Tiếng Việt)
Published: 2022-04-30
Abstract Views: 191
Views PDF (Tiếng Việt): 409
DOI: https://doi.org/10.52852/tcncyh.v152i4.703
Issue
Vol. 152 No. 4 (2022)
Section
Các bài báo
How to Cite
Huyền, T. T., & Lượng, V. H. (2022). Comparison of clinical and paraclinical characteristics of Stevens - Johnson syndrome and toxic epidermal necrolysis . Journal of Medical Research, 152(4), 69-78. https://doi.org/10.52852/tcncyh.v152i4.703

Comparison of clinical and paraclinical characteristics of Stevens - Johnson syndrome and toxic epidermal necrolysis

Tran Thi Huyen, Vu Huy Luong

Main Article Content

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions, although are rare incidence but the mortality rate can be up to 5-30%. SJS and TEN are classified as a spectrum of diseases but clinically, TEN is more severe than SJS. This study was conducted from January 2018 to October 2019 to compare some clinical and paraclinical characteristics of SJS and TEN. The results showed that the rate of pneumonia in the TEN group was higher than that in the SJS group (p < 0.05); the rate of oral mucous membrane lesions in the SJS group was higher than that in the TEN group (p < 0.05); the rate of allopurinol (as a causative drug) in the SJS group was higher than that in the TEN group (p < 0.05); the time of hospitalization of the TEN group was longer than that of the SJS group (p < 0.01). Serum levels of IFN-γ of the TEN group were higher than those of the SJS group (p < 0.001). Serum levels of granulysin, TNF-α, IL-2, IL-4, IL-5, and IL-13 did not differ between the two groups.

Article Details

Keywords

Keywords: Stevens-Johnson syndrome, toxic epidermal necrolysis, IFN-γ, granulysin, TNF-α

References

1. Bastuji - Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens - Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92 - 96.
2. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens - Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194 - 1227. doi:10.1111/bjd.14530
3. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens - Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343 - 1350. doi:10.1038/nm.1884
4. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug - specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209 - 1215. doi:10.1016/j.jaci.2004.07.047
5. Viard - Leveugle I, Guide O, Jankovic D, et al. TNF - α and IFN - γ are potential inducers of Fas - mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489 - 498. doi:10.1038/jid.2012.330
6. Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin - 15 Is Associated with Severity and Mortality in Stevens - Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017;137(5):1065 - 1073. doi:10.1016/j.jid.2016.11.034
7. Saka B, Barro - Traoré F, Atadokpédé FA, et al. Stevens - Johnson syndrome and toxic epidermal necrolysis in sub - Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):575 - 579. doi:10.1111/j.1365 - 4632.2012.05743.x
8. Saka B, Akakpo AS, Teclessou JN, et al. Ocular and Mucocutaneous Sequelae among Survivors of Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. Dermatol Res Pract. 2019:4917024. doi:10.1155/2019/4917024
9. Lương Đức Dũng, Hoàng Thị Lâm, Nguyễn Văn Đoàn. Đặc điểm lâm sàng, cận lâm sàng của hội chứng Stevens - Johnson và Lyell do dị ứng thuốc. Tạp Chí Nghiên Cứu Học. 86(1):15 - 21.
10. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol - induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157 - 2164. doi:10.1136/annrheumdis - 2014 - 205577
11. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758 - 766. doi:10.1111/1346 - 8138.13430
12. Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208(12):1968 - 1978. doi:10.1093/indices/jit383
13. Peña SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol Baltim Md 1950. 1997;158(6):2680 - 2688.
14. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004;123(5):850 - 855. doi:10.1111/j.0022 - 202X.2004.23439.x
15. Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens - Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69(3):496 - 498. doi:10.1016/j.jaad.2013.04.007